| Status: Under consideration by AWMSG Scrutiny Panel | |
For the off-label third line or later treatment of metastatic colorectal cancer (mCRC) as a re-challenge after previous successful first-line use of an epidermal growth factor receptor inhibitor (EGFRi). |
|
Medicine details |
|
| Medicine name | cetuximab (Erbitux®) |
| Formulation | 100 mg/20 ml and 500 mg/100 ml solution for infusion |
| Reference number | 6321 |
| Indication | As above |
| Company | Merck Serona Ltd |
| BNF chapter | Malignant disease & immunosuppression |
| Submission type | Under consideration |
| Status | Under consideration by AWMSG Scrutiny Panel |
| Scrutiny Panel meeting date | 09/01/2025 |